Clinical Progress in Antiangiogenic Therapy for Lung Cancer

I have read the CME Disclosures

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Providership of New York Medical College and the Angiogenesis Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

New York Medical College designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit will be awarded to those who complete this activity according to the instructions and achieve a score of 70% or better on the post activity examination. A certificate of credit will be available for download to those who successfully complete the examination.

Date of original release: June 13, 2014
Date of expiration: June 12, 2015
CME Course Code: 2014LUNG

Practicing oncologists, pulmonologists, and primary care physicians in the U.S., researchers and medical students

In the United States alone, more than 228,190 new cases of lung cancer are estimated to have be diagnosed in 2013, and an estimated 159,480 have died from this disease. Approximately 85% of lung cancers are a variety called non-small cell lung cancer (NSCLC), which are actually a number of tumor subtypes that originate in lung epithelial cells. The outlook for people with lung cancer that has spread (metastasized) to other organs of the body is almost uniformly grim: most patients with metastatic disease treated with standard chemotherapy survive for less than one year. Because of this poor prognosis, there is an urgent need for better treatments.

This activity is designed to address the following ABMS / IOM competencies: Patient Care and Medical Knowledge

There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website ( in the CME section. A print version is also available; for more information contact After reviewing the material, CME credits are available through the Angiogenesis Foundation's website ( by selecting the name of the program (registration required). Course code: 2014LUNG

This activity is supported by educational grants from Genentech, sanofi-aventis U.S. and Regeneron Pharmaceuticals.

William Li, MD
Dartmouth Medical College

New York Medical College asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. New York Medical College has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

William W. Li, M.D.
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.

Emerging Concepts in Targeted Therapy for Non-Small Cell Lung Cancer:

  • Clinical Progress in Antiangiogenic Therapy for Lung Cancer
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors in Phase 3 Trials
  • Angiogenesis Inhibitors and NSCLC in Asia
  • Biomarkers
  • Safety
  • Future Directions

This educational program is available as a mobile application and a PDF file. The mobile application can be run on any iOS or Android device. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site:

For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or